family with sequence similarity 86, member A pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM86LP profile across patient tissues and cancer cell-line models. FAM86LP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM86LP is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, FAM86LP RNA expression shows 11,569 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where FAM86LP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86LP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86LP survival associations across molecular data types. FAM86LP RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86LP RNA expression–survival associations across cancer types. High FAM86LP expression shows unfavorable associations in KIRC, THCA, ACC, PRAD, ESCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM86LP RNA expression.
This table summarizes FAM86LP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86LP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86LP shows lower tumor expression in LIHC and higher tumor expression in LUAD, STAD, BRCA, PAAD and ESCA. The LUAD box plot shows higher FAM86LP RNA expression in tumor versus normal tissue (log2 FC = +0.342, t-test p < 0.001).
This table shows molecular features associated with FAM86LP in patient tissues and cancer cell lines. In patient samples, FAM86LP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
